Author Archives: admin


Anatomy of a grant: Ashley Kramer’s yearlong journey to finding her doctoral thesis – The South End

He asked her for a list of dream projects she would love to investigate. What followed was a year of challenges, stresses and the ultimate reward guided intellectual freedom toward scientific discovery.

Ashley Kramer, a student at the Wayne State University School of Medicine, is enrolled in the schools M.D.-Ph.D. program, an eight-year commitment broken down into three parts the first two years of medical school, four years of graduate school, then the final two years of medical school. Like all M.D./Ph.D. students at the medical school, Kramer had to complete research rotations with faculty she thought would make good dissertation advisors.

Because I have always loved stem cell biology and had experience working with zebrafish in the past, I decided to do an eight-week rotation in Dr. Thummels lab between my medical year one and medical year two, and made the decision that this was absolutely the perfect lab for me, she said.

Ryan Thummel, Ph.D., is an associate professor of Ophthalmology, Visual and Anatomical Sciences. His lab focuses on retinal development and regeneration in zebrafish, an attractive model to study neurodegenerative diseases because of its ability to regenerate neuronal tissues. Zebrafish fully regenerate their retinas in just a matter of weeks, an ability mammals lack.

Zebrafish and mammals both have a cell called Mller glia that supports retinal neurons. In zebrafish, however, these cells convert to stem cells and are responsible for retinal regeneration.

At the end of the rotation, Dr. Thummel floated the crazy idea of starting to work on this grant, a 70-plus page monster undertaking, during my M2 year, and I immediately jumped at the opportunity. I was excited at the idea of having a four-year research project completely planned out by the time I started my Ph.D. after M2 so I could hit the ground running after the dreaded STEP 1, Kramer said.

I came to him two days later with a nine-page document of project ideas. We sat down for three hours discussing projects and came up with a top-two list of cohesive projects for me to move forward with as a grant and thesis, she said. From there, it was a nearly yearlong process of writing, meeting, revising and repeating for each of the many sections of the grant.

The effort was worth it. Kramer secured a five-year, $294,102 grant from the National Eye Institute of the National Institutes of Health last year to study the molecular mechanisms of retinal regeneration in zebrafish, an organism that exhibits a remarkable capacity for regeneration.

"Ashley is a dedicated young scientist and worked very hard on this grant application," Dr. Thummel said.

The grant is one of the NIHs Ruth L. Kirschstein National Research Service awards, also known as an F30. The project, Elucidating the role of DNA methyltransferases in epigenetic regulation of retinal regeneration in the zebrafish, started last month. She is the principal investigator.

This was an incredibly challenging experience that allowed me to grow immensely as a scientist. Grant writing, planning effective and novel longitudinal scientific investigations, and time management will all be critical skills for me moving forward in my career as a physician scientist, she said. I cannot thank Dr. Thummel and my past advisors enough for all of their mentoring and support in the last ten years who have gotten me to where I am today, and I am looking forward to the rest of my training here at Wayne State and beyond.

Kramer earned her bachelors degree in Genetics, Cell Biology and Development from the University of Minnesota in 2014. Her love of research and stem cell biology started when she was an undergraduate research assistant there.

Nearly a decade later, she is studying how epigenetic marks are added to, and removed from, genes in zebrafish retinal stem cells during the process of retinal regeneration. The role of epigenetics in the body is akin to traffic signs on the road.

If roads had no traffic lights, stop signs or barricades, it would be complete chaos. The same is true for your cells. If you used every single gene encoded in your DNA 100% of the time, your cells would be chaos. Epigenetics is what is responsible for telling your skin cell to be a skin cell and your liver cell to be a liver cell, while they both have the exact same underlying DNA sequence, Kramer said. There are various different epigenetic marks that decorate the DNA without actually changing the sequence. These marks come in many forms and can act to either start, stop or change the amount that a particular gene is used, similar to how a green light, road block or stop sign direct traffic rules.

The process is critical for normal embryonic development and everyday cell processes.

If we can gain a deeper understanding of how species like the zebrafish are able to regenerate tissues when mammals cannot, despite having the same cell types, we may be able to start working to translate those mechanisms to mammals, she said. It is possible that certain regeneration pathways have been epigenetically silenced through evolution and we may be able to use modern advances in gene therapy techniques to unlock regenerative capacity in mammals.

Follow this link:
Anatomy of a grant: Ashley Kramer's yearlong journey to finding her doctoral thesis - The South End

The Challenge of Bioethics to Decision-Making in the UK – Westminster Abbey

Past Institute lectures

A lecture for the Von Hugel Institute series Ethics in Public Life, 5th February 2015, given by Claire Foster-Gilbert, Director, Westminster Abbey Institute.

The context of the series of lectures of which this is one is ethics in public life, and I would like to start by taking some time to describe the creation and operation of Westminster Abbey Institute, and use it as a prism for our consideration of bioethics and decision making in the UK. I want to say a little bit about the sacred-secular divide which I do not see. Then the two thorny examples I will use in bioethics, when I come to them, will be embryology and assisted dying.

Westminster Abbey Institute was launched in November 2013 to revitalize moral and spiritual values in public life, working with the public service institutions around Parliament Square, and drawing on its Benedictine resources of spirituality and scholarship.

Westminster Abbey sits on the south side of Parliament Square, with the Judiciary in the form of the Supreme Court on the west side, the Executive in the form of Whitehall on the north side, and the Legislature in the form of the Houses of Parliament on the east side. The Institute is the Abbeys answer to the question: what is it bringing to public service and how can it support those in public office?

We knew, when we started, what we were not: a think tank, part of the commentariat, a campaigning organisation, nor a fawning courtier. Nor were we apologists for religion in the public square. The Abbey is already more integrated than that. There is no sense of a sacred-secular divide, and as I go about my work as Director I feel none between my work and that of the public service institutions around the Square. The similarity is that we are identifying at the heart of the Parliament Square endeavour a sincere wish to support the good, to serve society, to make things better in the world. And in that sincere wish I see spirit moving, hearts opening, minds analysing, bodies acting, as a holistic, responsive flow to the call of public service.

I am not naive: the motivation to serve the public and the vocation to public service are not pure. In amongst the good wheat of service are the tares of motives such as selfish ambition, personal gain, fame, and the needy weakness of human nature to be recognised and rewarded. I see those other motives, but I know them for my own also, so am in no position the Abbey Institute is in no position, lets be clear to judge or condemn them. Like the parable, we leave that till the harvest. And meanwhile, by supporting the good, believing in the motives that are for service, recognising and applauding the rightness in the work around the Square, the murky tares, if I may torture the analogy beyond its capability, melt away. We hope.

I see a wholeness, then, responding to a call to serve. The deeper the response the more effective and lasting it will be and here is a place where our religion makes a specific contribution. The further back into God it reaches, the more effective and lasting and good the call to public service will be. I call it God. Spirit, depth, the swirling deep movement of creativity, the meditation of the soul, the rest before action. The further the archer draws back the bow, the further and truer the arrow will fly. It has been notable just how much of a longing for depth has shown itself in the people and institutions around the Square in the short time the Institute has been operating.

Our method is first to offer a Benedictine context. That is, we offer conversation that locates itself in stability, community and the conversion of manners. We will sit down with a group of, say, senior Civil Servants, or those tasked with offering professional development to MPs, or a group of Peers, and together we will devise a seminar for their department or group which will look at the good that the department or group is trying to do. What is significant and distinctive is that the psychological and philosophical location of the conversation is deep. That depth is also physically expressed by the Jerusalem Chamber where King Henry IV died and V became King, and the King James Version of the Bible was finalised, and so forth, where the seminars happen. Part of the Abbots and then the Deans lodging, a space where spiritual and worldly do not separate.

I was set a great example of how to do depth by Rowan Williams when he was the interlocutor for a series of four public conversations at St Pauls Cathedral, taking in turn global economy, ecology, governance and health, and asking the experts in those fields questions which immediately drew them into a consideration of the philosophical and even theological underlying currents of the subjects. The bishops did a similar thing with genetics experts when they spent a day learning about the subject. They were really good questions, and ones that practitioners, officials, public servants often dont have time to ask, but they are the most important questions because they lead us into our spiritual humanity.

A really lovely example emerged yesterday when we were sitting around the table in the Permanent Secretarys office of a Government Department, discussing a forthcoming seminar for the Department. One of the Civil Servants spoke about how too often officials in the Department will apply formulaic approaches, such as the benefit-cost ratio, in a way that masks or even undermines vital human qualities such as empathy and humility, and we will look at this in the seminar. Importantly, the words and the disposition came from the Civil Servant, not from the Abbey Institute. We are not functioning on the Square to tell others what the Good is. It emerges in the encounter.

So the conversation is located in a Benedictine place (in a way, for a short while, that Permanent Secretarys office became a Benedictine space). First, it is stable, it is safe here, and here is not going to go away, its an historical place where we can feel our own passing, gain a perspective on our place in history. Second, it is a place of community, which means that we are gathered in goodwill together, seeking the good together, united in our efforts and made companions in our purpose, not by any means agreeing with each other but feeling safe with each other. As a community of goodwill we feel it is safe to get things wrong, to take time to form conscience, to work things out. And of course we operate to the Chatham House rule. Third, we are about the conversion of manners. We expect transformation to take place though we dont necessarily know what it will be. Broadly, though, borrowing from Philip Shepherd, we will be looking for moves:

And I dont mind admitting that this transformation is probably only realised after the talking is over and everyone has gone to evensong and then wandered around the Abbey in the semidark and silence of the close of the day and had a glass of wine back in the Jerusalem Chamber!

In agreeing that we are a community of goodwill seeking to articulate the good I have offered an analogy from sailing that works well. A Government Department can be imagined as a sailing boat. At the helm stands the Permanent Secretary, who, like all good helmsmen, seeks never to steer the boat more than five degrees either side of the compass direction upon which the boat is set. Civil Servants in the Department form the crew, from the navigator who must know the course and ensure the helmsman anticipates obstacles, to the scrubber of decks who ensures no one slips up. All play their part in ensuring the boat remains shipshape and able to withstand the waves and the winds in travelling its appointed course.

The waves are the events of the nation and the world. They may be relatively calm or they may rise into steep and stormy mountains of water, threatening the stability of the boat.

The winds are public opinion, which can fill the sails of the boat and send it scudding on its chosen course. They can gust and buffet, interrupting the boats smooth journey. Or they can blow adversely, threatening to push the boat off course altogether.

Hence, the helmsman cannot simply hold the tiller fixedly. He or she must constantly respond and adjust to the wind and the waves, aiming to keep within five degrees either side of the compass direction or risk increasingly over-compensatory swings away from the course of travel.

The compass point towards which the boat is sailing is The Good. As such, it is not a destination; the journey is the thing, the direction of travel the concern, not the arrival.

By whom is The Good defined? It is true that the Government Minister is granted that responsibility and privilege by virtue of having been elected by universal franchise. But in defining The Good, Ministers have to have their Partys support. And of course the strength of the prevailing wind, public opinion, may be such as to determine a change of compass direction altogether. For the politician, public opinion will set parameters on what he or she can achieve. The great political leader will have a vision of the Good that transcends narrowminded concerns but retains Party support, and respects the parameters set by the prevailing wind of public opinion. The visionary and skilled politician will learn, quite possibly from his or her Civil Servants, about the art of tacking.

Because of course it is the helmsman and the crew who execute the tack, and any other sailing manoeuvres required. The Civil Service crew, having gathered the evidence sniffed the wind, watched the waves will need to be able to tell Ministers when their proposed direction of travel will not work: when, whatever the Ministers might want to think, their proposed direction is possibly not towards The Good. Thus the Good is sought by all.

And in passing, if one imagines Whitehall as a fleet of boats, those, too, will need to be taken into account by the helmsman. But and it is a wonderful sight sailing boats, journeying as a fleet in the same direction across the waves, subject to the same wind, stay uniform distances apart.

Having established a common concern with identifying the Good, seated in our Benedictine space, we then spend time as moral philosophers, looking at the specifics of the policy drivers for a given Government Department. Our analysis is rigorous, using the method I developed in the Centre of Medical Law and Ethics at Kings College, London, under Ian Kennedy, in the 1990s.

We use the three broad approaches that moral philosophers have taken over the centuries as they have sought to determine what is good. These we have called goal-based, duty-based and right-based, following Dworkinii, Botrosiii and Fosteriv. Very briefly and broadly, a goal-based thinker will see the good of an action in its consequences rather than in the content of the action itself; a duty-based thinker will look at the action and judge it according to preexisting moral rules; and a right-based thinker will judge the action according to the views of those most affected by it. The goal-based approach is valid insofar as it is the case that we rarely act without some end in view and it is right to consider whether that end is a good one. The goal-based approach is limited in that even very desirable goals should not justify actions which in themselves are intrinsically nasty. The ends are important moral considerations but they dont justify the means. Morality is not a mathematical exercise. The duty-based approach is valid in that it makes us think hard about what we are doing rather than merely why we are doing it, recalibrating the needle of our moral compass, making us morally sensitive rather than mathematically certain. The duty-based approach is limited because it can blind us to important consequences (Kant would have us truthfully respond to a murderer seeking her prey); and it is limited because it can make us arrogant: concerned only with our own place in heaven earned by doing the right thing, regardless of its effect or the views of others (the poor soul who will be murdered because Kant refused to tell a lie, or the patient who wants his life support switched off and we refuse to take a life). The right-based approach is valid because it requires us to listen to others, it makes us community-minded instead of purist. It is limited because on its own it would make someones request, for example, to take their life, right with no other consideration except that it is their wish.

All three approaches are needed. They conflict, they make us think, they require sensitive responses, honest appraisal, self-awareness because we will temperamentally favour one approach over the others, but taken together they form a three-legged stool that stands firm, if the legs are all of the same length, even on rocky ground.

And then comes the real challenge of bioethics. The Department of Health wants us all to live better for longer. But when does life begin and when does it end? I want in this third and final part of my lecture to explore the contemporary challenge of these questions by looking at two issues embryology and assisted dying that have been working their way around Parliament Square, with cases in the Supreme Court, policy development in Whitehall, and legislation or attempts at legislation in the Houses of Parliament.

Human fertilisation and embryology are scientifically complex and they are also, at every stage, morally sensitive. The challenge to Government and Parliament has been whether and how to draw these extraordinary scientific developments within a regulatory framework in a way that respects the science and does not ride roughshod over the sensitive moral questions, or ban the research and practice altogether. Having chosen the former course of action, what principles needed to underlie the regulatory framework?

Let us take a step back in time and thought. Let us bring the issue into our safe Benedictine space. Here we are allowed to think out aloud. We do not have to have a pre-determined position, but if we do, we wont be shouted down or assumed to be on the side of the devil.None need feel defensive. In this Benedictine space we are seeking the Good, aware that many have tried before us and God willing there will be many afterwards, all calibrating their moral compass and seeking to steer the boat no more than five degrees either side of the compass point, but having to allow, because of the wind of public opinion and the waves of ever changing events, that much leeway either side. We know we will not find perfect answers.

And now for the three-legged framework. From a goal-based perspective, we ask what embryology is for, and why it matters. Embryology is important as a cure for infertility, as a therapeutic response to currently incurable diseases using cell transplantation and, very recently proposed, eliminating mitochondrial disease altogether. Its goals, then, are for life: new life, and curing diseased life. No one, really, could argue with the goals of embryology. We would want the research and practice to be done excellently, so as to ensure these good goals were reached, but from a goal-based perspective, taken on its own, there can be no quarrel with it.

From a duty-based perspective, what does embryology involve? Here the moral questions start to bite. The first question must be about the status of the embryo itself. Because if the embryo has the same status as a human life, no matter how wonderful the goals are, no one would countenance destroying a human life to reach them, and embryology (which always involves destroying embryos) would fall at this moral fence.

The reasons you might regard the embryo as a human life are as follows: the embryo is formed from the fertilisation of an egg by a sperm forming a unique genome no one (if it is a person) was ever like it before, and no one will be ever again. We, each of us diverse people, were all embryos once. If we are to choose a point when life begins, the formation of the fertilised egg is certainly a definite stage one could choose.

The reasons you might not regard the embryo as human life are: the place of fertilisation is not the womb or the field in which the embryo is implanted, but at the base of the fallopian tubes. The embryo still has a journey to make to reach the womb and implant. (Some Shia teaching on this argues that life cannot be said to have begun until the seed, egg and field are all in place, ie at implantation.) During that journey, in the normal course of events, 70% of embryos do not reach the womb. It is during that journey that the all-important stem cells start to proliferate, hence the interest in the early, pre-implanted embryo, not the fetus in the womb. During that journey, the embryo may divide and become more than one fetus, hence genetically identical twins. These reasons may persuade you that it would be acceptable to see the early embryo not as human life but as potential life, and that its use therapeutically is acceptable. You may feel the goal-based tug: the status of the early embryo is in question, and the use of them therapeutically is so full of promise Should the duty-based consideration, that the embryo has independent moral status like that of a human being, give way?

What is important to recognise is that we do not say that the embryo has no status. The legislation has recognised its moral importance by regulating its use. But the law has accepted that the embryo is not the same as a human life.

From a right-based perspective, you cannot really make a judgement. The embryo cannot speak for itself. Is it fanciful to conduct a thought-and-feeling experiment predicated on the fact that we were all embryos once. Would we be happy to have been destroyed even before reaching the womb, to save another life or lives, or to create a new life? ??

The other right-based question relates to those who might benefit from stem cell or mitochondrial therapy: if they think of the embryo as having human status they may not want to benefit from such treatment. Healthcare practitioners may seek to be conscientious objectors.

The challenge to UK decision-making of embryology has been profound and I think, myself, that we have not done badly at it. Prior to this last development on mitochondrial DNA, the debates have been long and thoughtful, no speedy legislation was drawn up (except to prevent cloning), and the regulation is careful. In the UK, embryo research can take place but it is all regulated. (In the US, embryo research may not take place if it is federally funded; if you can pay for it yourself, you can do what you like!)

However, courts continue to be referred to as no legislation could possibly anticipate the science. It has turned out that the most fruitful source of embryonic stem cells has not come from embryos but from de-differentiated adult cells. Since however these de-differentiated cells, if placed in a womb, could theoretically grow into a clone of the person whose cell it was, this has had to be specifically outlawed and, much more recently, and potentially worryingly, a court has ruled that: The mere fact that a parthenogenetically activated human ovum commences a process of development is not sufficient for it to be regarded as a human embryo. This judgement opens the way to patenting the process of creating stem cells. It is potentially worrying since it arguably robs the embryo of its moral status. However, what is the status of a de-differentiated cell, which could originate from any one of the bodies in this room just by scraping our skin?

Is the very recent decision of the Commons to allow the process that removes diseased mitochondrial DNA from the offspring of mothers with the disease a case of slipping down a slippery slope into unethical waters? Is it the first step towards eugenics, since it eliminates the disease from the germ line permanently? Or is it an intelligent use of skills and techniques we have developed through carefully regulated embryo research, that will allow the cure of a vile disease?

Assisted dying, unlike embryo research, has not been made legal and given a set of regulations by which to abide. Despite its repeated return to Parliament and the apparent public support for a change in the law, none has happened, as yet. In practice, cases have been decided by the Courts and the number of cases coming to the Courts is only increasing. It is something of a sore point for the judges: they cannot turn cases away. All the time, as they see it, Parliament refuses to take the bull by the horn and create legislation, they are obliged to give judgements on a case by case basis that creepingly changes the law, and it is changed by lawyers not by democratically elected representatives of the public debating in public.

Before reflecting on the challenge to law and policy-makers that assisted dying has posed, let us once again step back into our Benedictine space, and we should pause here for a moment and recollect that the primary quality of that space is listening

And now conduct our analysis. Assisted dying is the act of making available to a person, who has expressly and competently asked for it, the means to take his or her life by their own hand.

From a goal-based perspective, one goal of assisted dying is to alleviate suffering. Another is torespect the autonomy of individuals. Another may be put more boldly: to end life deliberately.

From a duty-based perspective, principles of the sanctity of life and of respecting autonomy both raise their concerns, and conflict. How are they resolved?

From a right-based perspective, the principle of respect for autonomy trumps any duty of other individuals to save, sustain or end life. It is, simply, up to the individual. When polls are taken on the subject of assisted dying and euthanasia the vast majority of responses are in favour of it, on the grounds, though, that it is my life to do with as I please and who is any doctor to prevent me. But a law that permitted a solely right-based approach that the request should be granted simply because it had been made would be impossible to apply. It would be impossible to know if the person had actually asked for death, because they would be dead. Additional safeguards have to be included in any legislation, and these require that certain relevant professionals are satisfied that the conditions allowing assisted dying are met. This is not, then, a purely rights-based activity any more. Similar difficulties arise in seeking abortion - it is not, in the legislations, simply up to the mother whether or not the abortion takes place. She has to satisfy two doctors that she fulfils the criteria set by the law. The fact that doctors will very often sign the forms without questioning the mother, because they take a right-based approach in profoundly believing in her right to choose, is symptomatic of the challenge of lawmaking in areas of bioethics.

If the dying in question is assisted only, ie the person has to take the lethal substance themselves, this right-based problem is allayed. That is to say, we may be fairly sure that if the pink drink given by organisations such as Dignitas is drunk without assistance once it is put in the hands of the one seeking assisted dying, then he or she most definitely did want to die.

We cannot know what passes in their hearts however, and Mary Warnock has been worryingly at ease with the idea that it would be perfectly all right to seek euthanasia on the grounds that one felt a burden to ones family and friends. The wishes and needs of the community of that individual: family, loved ones, society are all included in the right-based approach, and what of these? Chaplains ministering to those receiving euthanasia in Holland speak of the devastation of families, resonant of the desolation of the families of suicides.

The most recent case that came to the Supreme Court was that of Nicklinson, Lamb and the Director of Public Prosecutionv. Nicklinson and Lamb were both almost entirely paralysed; Nicklinson from a stroke which left him able to blink only and Lamb from an accident that meant he could only move his right hand. Hence neither would be able to take the pink drink unaided, so both wished to be assisted to die without fear of prosecution of those who helped. The Director of Public Prosecution sought the freedom to decide on the matter of assisting suicide on a case by case basis.

In the Supreme Court, all the Law Lords agreed that Article 8 of the Human Rights Act (which is the right to a private life, to be overridden only in the case of threats to public safety or criminal acts) is relevant to the issue of assisting someone to die if it is their express wish. That is to say, domestic rulings can be made by way of interpretation of the Article in relation to assisted suicide. But while some Law Lords believed that it was a right for a person to be assisted to die if it was their express wish, according to Article 8, others did not. It was recognised that there was a fundamental incompatibility between the sanctity of life and autonomy. Several Law Lords argued strongly that the debate should be held in Parliament as the representative body of society, not judged upon by appointed Justices. And indeed there is yet another bill to allow assisted dying making its way through the House of Lords now. It has reached the stage where the Lords are working through more than 100 amendments, some of which are clearly intended to wreck the bill, whilst others provide clarification and strengthening of safeguards. And arguably the intellectual purity of the moral reasoning of the judges is a better place to turn to than the mess of Parliamentary debate. What a strange way for law on such a sensitive and controversial issue as the management of the dying process to be written: by the tug of war of differing factions and the compromise that will inevitably be reached if the bill is to succeed.

And yet, how are we to decide these matters that affect us all? I should like to finish, provocatively, with a lengthy quotation from a recent lecture delivered by one of the Justices of the Supreme Court, Lord Sumption.

To sum up, then. We have considered challenging and complex bioethical issues using the Westminster Abbey Institute approach of first, creating a Benedictine space of safety and stability, second, subjecting the matter to rigorous moral analysis and third, coming to a decision, which decisionmaking is the responsibility of the lawmakers and the policymakers. What I have not done is to offer absolute rules or principles which trump every other consideration. It is far better to be morally sensitive than to be morally certain. And so I am agreeing with Lord Sumption that, however fallible it may be, Parliament is the place to fashion legislation on these matters. We do well to attend to whom we put there.

(i) Philip Shepherd, New Self, New World: recovering our senses in the twenty-first century, (Berkeley: North Atlantic Books), 2010 (p 282)(ii) Ronald Dworkin, Taking Rights Seriously, 1977 (Harvard: Harvard University Press)(iii) Sophie Botros and Claire Foster, The moral responsibilities of research ethics committees, in Dispatches, 3:3, Summer 1993(iv) Claire Foster, The Ethics of Medical Research on Humans, (Cambridge: Cambridge University Press) 2001(v)R (on the application of Nicklinson and another) (Appellants) v Ministry of Justice (Respondent); R (on the application of AM) (AP) (Respondent) v The Director of Public Prosecutions (Appellant); R (on the application of AM) (AP) (Respondent) v The Director of Public Prosecutions (Appellant) 25 June 2014(vi) Lord Sumption, The Limits of Law, 27th Sultan Azlan Shah Lecture, Kuala Lumpur, 20 November 2013

Download a transcript of this lecture (PDF, 238KB)

Continue reading here:
The Challenge of Bioethics to Decision-Making in the UK - Westminster Abbey

Platelet-rich plasma therapy (PRP): Costs, side effects …

Platelet-rich plasma therapy has made headlines, often because it is favored by elite athletes to help them recover from injury.

Some doctors are now using platelet-rich plasma therapy or PRP injections for several reasons, from encouraging hair growth to promoting soft tissue-healing.

However, research studies have not definitively proved that PRP works for the conditions it is reported to benefit. In this article, we have a look at the case for PRP, and the costs involved.

Platelets are blood cells with several roles to play in the body.

One is to promote blood clotting so that a person does not excessively bleed when they are cut.

Another is to contain proteins in the blood that help wounds to heal.

Researchers theorize that by injecting areas of inflammation or tissue damage with high concentrations of platelets, it can encourage wounds to heal.

A small blood sample is taken from the person being treated and put into a centrifuge or other specialized device that spins at high speed. This process separates platelets from other blood components. The concentration of platelets is then injected into the area of the persons body that needs to be treated.

Because the injection contains a high concentration of platelets, which can be from 5 to 10 times more than the untreated blood, doctors theorize that the platelets will speed up healing.

Some examples of treatment areas where PRP has been used include:

Doctors have injected PRP into the scalp, as a way of reducing the inflammation that can lead to hair loss.

Doctors first used PRP to help people heal after jaw and plastic surgeries. Examples of tissues that PRP has been used on include:

Ligaments can take time and be difficult to heal, which can make PRP an attractive option for some of those who have experienced injuries to this tissue group.

Doctors have used PRP to reduce inflammation caused by osteoarthritis. This inflammation can lead to joints becoming painful and stiff.

Research studies about PRP include:

Doctors are also trying to use PRP to heal broken bones, but no research has yet proven its effectiveness in this area.

Costs for PRP treatment are reported to be between $500 and $2,000.

It is not typically covered by insurance because of the lack of evidence, so far, to conclusively prove that it works.

Also, costs can vary depending on location, facilities, and the expertise of the doctor performing the treatment. Often, a person will have multiple injections given 2 to 3 months apart.

Some of the worlds most elite athletes have used PRP for wound healing. They include golfs Tiger Woods, baseballs Takashi Saito, and footballs Hines Ward and Troy Polamalu.

As injecting PRP involves using a persons own platelets, they do not usually experience any adverse reactions to the injections. However, it is possible that a person may have irritation, pain, or bleeding related to the injection site.

Most people can resume their normal activities almost immediately after having a PRP injection. The average time from blood-drawing to the injection itself is about half-an-hour.

While PRP is a promising therapy for those who experience tissue damage or hair loss, large-scale research studies are needed to establish the effectiveness of treatments.

With larger studies than those to date, doctors could identify a dose or injection routine that works best for treating injuries or other conditions. Also, further studies could help doctors determine what symptoms to exclude from PRP injections.

Until that time, PRP injections are likely to remain a controversial therapy not covered by medical insurance, the costs of which, people are required to pay for themselves.

The rest is here:
Platelet-rich plasma therapy (PRP): Costs, side effects ...

New informative research on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 | Major Players: Orange County Hair Restoration…

This industry research presents the Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market size, historical breakdown data (2014 2019) and forecast (2020 2025). This report provides the estimation of market size and volume. Both top-down and bottom-up approaches have been used to estimate and validate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Market study on the global market will encompass the entire ecosystem of the industry, covering five major regionsand the major countries falling under those regions.

Download Exclusive Free Sample PDF Report at https://inforgrowth.com/sample-request/5930924/stem-cell-and-platelet-rich-plasma-prp-alopecia-th

Following Top Key players are profiled in the report:Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute.

The Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report analyzes and researches the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development status and forecast in United States, EU, Japan, China, India and Southeast Asia.

Market Segmentation:

The Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market report focuses on global major leading industry players providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out.

On the basis of products, the report split into: Platelet Rich Plasma Injections, Stem Cell Therapy

On the basis of the end users/applications:Dermatology Clinics, Hospitals

Get Special Discount Up To 50%,https://inforgrowth.com/discount/5930924/stem-cell-and-platelet-rich-plasma-prp-alopecia-th

Key Stakeholders as per this report are Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Manufacturers, Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Distributors/Traders/Wholesalers, Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Subcomponent Manufacturers, Industry Association, Downstream Vendors.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects are assessed and overall research conclusions offered.

With the tables and figures, theStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Furthermore, this Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market study will help our clients solve the following issues:

This study will address some of the most critical questions which are listed below:

Get Complete TOC: https://inforgrowth.com/enquiry/5930924/stem-cell-and-platelet-rich-plasma-prp-alopecia-th

Contact Us: Contact Person: Rohan S. Email:[emailprotected] Call: US: +1-909-329-2808 UK: +44-203-743-1890

Go here to see the original:
New informative research on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 | Major Players: Orange County Hair Restoration...

Konica Minolta Healthcare Expands Ultrasound Guided Solutions Through Partnership with RegenLab USA – Yahoo Finance

WAYNE, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc. announces a newly formed partnership with RegenLab USA LLC to distribute its regenerative medicine portfolio of bio-injectable products to the musculoskeletal (MSK), pain management, radiology and veterinary markets in the United States and Canada. The bio-injectable line includes preparation devices for Platelet Rich Plasma (PRP) and other blood cell therapies, delivered using ultrasound guidance. This partnership further broadens Konica Minoltas UGPro Solution, a comprehensive program that unites ultrasound imaging with targeted therapies and hands-on education to help improve patient outcomes.

The regenerative medicine market for sports medicine, orthopedics and pain management is experiencing rapid growth and projected to exceed $300 million in North America by 20251. This growing demand for PRP and other cell therapies aligns with our UGPro strategy of bringing the highest quality, clinically validated solutions to our customers, says Kirsten Doerfert, Sr. Vice President of Marketing, Konica Minolta Healthcare. Our alliance with RegenLab is founded on our mutual belief in the importance of clinical evidence and the desire to help our customers better serve their patients.

PRP is a concentration of platelets in plasma from a patients own blood (autologous). The preparation kits from RegenLab allow for the easy, rapid and consistent preparation from a small volume of blood with an optimal platelet concentration and viability. Procedures are performed under ultrasound guidance to allow the practitioner to visualize the needle in real time and precisely place the injectate in the desired location. With ultrasound guidance, the accuracy of nearly every joint injection exceeds 90%.

Patients are seeking less invasive, results-oriented therapies for MSK and orthopedic injuries, says Eric Sumner, Executive Vice President Ultrasound Sales at Konica Minolta. Our partnership with RegenLab gives our customers a complete solution, from the highest quality ultrasound systems to excellent PRP and cell therapy products, so they can maximize the quality of care for their patients and get them back to being active again. We are excited to add RegenLabs biologic therapies to our comprehensive UGPro Solution.

Story continues

The single use PRP kits are designed to consistently prepare high-quality PRP and other cellular therapies that clinicians can safely and easily deliver in their practice. As a leading innovator for the preparation of PRP, safety and efficacy of our products is paramount, says Antoine Turzi, Founder and CEO of RegenLab. Our alliance with Konica Minolta Healthcare further advances this area of medicine by giving physicians the ability to guide the accurate delivery of cell therapy prepared with RegenLab products.

Ultrasound injections also have the advantage of giving real-time feedback, where the physician is not only able to observe the treatment being delivered, but also visualize surrounding structures. Konica Minoltas SONIMAGE HS1 Compact Ultrasound System delivers superior image quality along with Simple Needle Visualization (SNV) technology that improves needle visibility so that clinicians can confirm proper placement of biologics. To help address the growing need for ultrasound-guided procedures and education, Konica Minolta Healthcare launched the UGPro Solution in 2018.

Konica Minolta Healthcare and RegenLab USA are committed to innovation that truly makes a clinical difference.

1Grand View Research

About Konica Minolta Healthcare Americas, Inc.

Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. With over 75 years of endless innovation, Konica Minolta is globally recognized as a leader providing cutting-edge technologies and comprehensive support aimed at providing real solutions to meet customer's needs and helping make better decisions sooner. Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a unit of Konica Minolta, Inc. (TSE:4902). For more information on Konica Minolta Healthcare Americas, Inc., please visit http://www.konicaminolta.com/medicalusa.

Contact:Mary Beth MassatMassat Media224.578.2388www.konicaminolta.com/medicalusa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/be3abedc-dd46-42f5-87a4-39e1555f3384.

Continue reading here:
Konica Minolta Healthcare Expands Ultrasound Guided Solutions Through Partnership with RegenLab USA - Yahoo Finance

Improving shoes, showers, 3D printing: research launching to the Space Station – Space Daily

Houston TX (SPX) Feb 21, 2020A variety of science investigations, along with supplies and equipment, launch to the International Space Station on the 20th SpaceX commercial resupply services mission. The Dragon cargo spacecraft is scheduled to leave Earth March 2 from Space Launch Complex 40 at Cape Canaveral Air Force Station in Florida. Its cargo includes research on particle foam manufacturing, water droplet formation, the human intestine and other cutting-edge investigations.

The space station, now in its 20th year of continuous human presence, provides opportunities for research by government agencies, private industry, and academic and research institutions. Such research supports Artemis, NASA's missions to the Moon and Mars, and leads to new technologies, medical treatments and products that improve life on Earth.

High-tech shoes from spaceParticle foam molding is a manufacturing process that blows thousands of pellets into a mold where they fuse together. The shoe company Adidas uses this process to make performance midsoles, the layer between the sole of a shoe and the insole under your foot, for its products.

The BOOST Orbital Operations on Spheroid Tesellation (Adidas BOOST) investigation looks at how multiple types of pellets behave in this molding process. Using one type of pellet creates a foam with the same properties throughout the sole component. Using multiple pellet types can allow engineers to change mechanical properties and optimize shoe performance and comfort. Removing gravity from the process enables a closer look at pellet motion and location during the process.

Results of this investigation could demonstrate the benefits of microgravity research for manufacturing methods, contributing to increased commercial use of the space station. New processes for particle foam molding could benefit a variety of other industries, including packaging and cushioning materials.

New facility outside the space stationThe Bartolomeo facility, created by ESA (European Space Agency) and Airbus, attaches to the exterior of the European Columbus Module. Designed to provide new scientific opportunities on the outside of the space station for commercial and institutional users, the facility offers unobstructed views both toward Earth and into space. Experiments hosted in Bartolomeo receive comprehensive mission services, including technical support in preparing the payload, launch and installation, operations and data transfer and optional return to Earth. Potential applications include Earth observation, robotics, material science and astrophysics.

Airbus is collaborating with the United Nations Office of Outer Space Affairs to offer UN Member States the opportunity to fly a payload on Bartolomeo. Developing countries are particularly encouraged to participate, and the mission is devoted to addressing the UN's Sustainable Development Goals. Bartolomeo is named for the younger brother of Christopher Columbus.

Conserving water in the showerDroplet Formation Studies in Microgravity (Droplet Formation Study) evaluates water droplet formation and water flow of Delta Faucet's H2Okinetic showerhead technology. Reduced flow rates in shower devices conserve water, but also can reduce their effectiveness. That can cause people to take longer showers, undermining the goal of using less water. Gravity's full effects on the formation of water droplets are unknown, and research in microgravity could help improve the technology, creating better performance and improved user experience while conserving water and energy.

Insight gained from this investigation also has potential applications in various uses of fluids on spacecraft, from human consumption of liquids to waste management and use of fluids for cooling and as propellants.

Studying the human intestine on a chipOrgan-Chips as a Platform for Studying Effects of Space on Human Enteric Physiology (Gut on Chip) examines the effect of microgravity and other space-related stress factors on biotechnology company Emulate's human innervated Intestine-Chip (hiIC). This Organ-Chip device enables the study of organ physiology and diseases in a laboratory setting. It allows for automated maintenance, including imaging, sampling, and storage on orbit and data downlink for molecular analysis on Earth.

A better understanding of how microgravity and other potential space travel stressors affect intestine immune cells and susceptibility to infection could help protect astronaut health on future long-term missions. It also could help identify the mechanisms that underlie development of intestinal diseases and possible targets for therapies to treat them on Earth.

Toward better 3D printingSelf-assembly and self-replication of materials and devices could enable 3D printing of replacement parts and repair facilities on future long-duration space voyages. Better design and assembly of structures in microgravity also could benefit a variety of fields on Earth, from medicine to electronics.

The Nonequilibrium Processing of Particle Suspensions with Thermal and Electrical Field Gradients (ACE-T-Ellipsoids) experiment designs and assembles complex three-dimensional colloids - small particles suspended within a fluid - and controls density and behavior of the particles with temperature. Called self-assembled colloidal structures, these are vital to the design of advanced optical materials, but control of particle density and behavior is especially important for their use in 3D printing. Microgravity provides insight into the relationships among particle shape, crystal symmetry, density and other characteristics.

Functional structures based on colloids could lead to new devices for chemical energy, communication, and photonics.

Growing human heart cellsGeneration of Cardiomyocytes From Human Induced Pluripotent Stem Cell-derived Cardiac Progenitors Expanded in Microgravity (MVP Cell-03) examines whether microgravity increases the production of heart cells from human-induced pluripotent stem cells (hiPSCs). HiPSCs are adult cells genetically reprogrammed back into an embryonic-like pluripotent state, which means they can give rise to several different types of cells. This makes them capable of providing an unlimited source of human cells for research or therapeutic purposes. For MVP Cell-03, scientists induce the stem cells to generate heart precursor cells, then culture those cells on the space station for analysis and comparison with cultures grown on Earth.

These heart cells or cardiomyocytes (CMs) could help treat cardiac abnormalities caused by spaceflight. In addition, scientists could use them to replenish cells damaged or lost due to cardiac disease on Earth and for cell therapy, disease modeling and drug development. Human cardiac tissues damaged by disease cannot repair themselves, and loss of CMs contributes to eventual heart failure and death.

Related LinksISS National LabSpace Tourism, Space Transport and Space Exploration News

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.

Link:
Improving shoes, showers, 3D printing: research launching to the Space Station - Space Daily

In Vitro Fertilization Market will Reach USD 36.39 Billion by 2026: Increasing Cases of Infertility Among Men to Positively Influence Growth, says…

Key Companies Covered in the IVF Market Research Report are Monash IVF, Ovation Fertility, Bloom IVF Centre, Shady Grove Fertility, Bangkok IVF center, Boston IVF, Pelargos IVF, RSMC, Group Ambroise Par Clinic and other key market players.

Pune, Feb. 20, 2020 (GLOBE NEWSWIRE) -- The global In Vitro Fertilization (IVF) Market size is prophesized to reach USD 36.39 billion by 2026, with a CAGR 10.1% by 2026. This is attributable to the increasing cases of infertility among people worldwide. This is more common in males than female partners. The market value was USD 16.89 billion in 2018. IVF is a fertilization process wherein sperm and eggs are retrieved as a sample and are combined manually in laboratories. Various studies show that almost half a million babies are born by this process or other assistant reproductive processes. Such factors are responsible for the in vitro fertilization market growth.

Fortune Business Insights latest report, titled, In Vitro Fertilization (IVF) Market Size, Share & Industry Analysis, By Type (Conventional IVF, and IVF with ICSI), By Procedure (Fresh Non-donor, Frozen Non-donor, Fresh Donor, and Frozen Donor), By End User (Hospitals, and Fertility Clinics) and Regional Forecasts, 2019-2026 provides a 360-degree overview of the market and its parameters. These include growth drivers, restraints, challenges, and opportunities. The report also provides detailed segmentation of the market with market figures such as base and forecast figure and the compound annual growth rates (CAGRs) as well. Besides this, the report provides interesting insights into the market, key industry developments, and other IVF market trends. The report is available for sale on the company website.

Nowadays, people are more inclined towards career goals rather than family planning, and therefore often tend to opt for late pregnancies. The increasing number of such cases is a major in vitro fertilizer market driver, as mentioned earlier, since complicated cases are often resolved by opting for IVF treatment. This is more common in nations such as the UK, Japan, and the U.S. Besides this, the rise in the number of male infertility is anticipated to increase the adoption of IVF treatment and thus accelerate the in vitro fertilization market size in the coming years. Besides this, government-supported reimbursement policies and awareness programs are aiding the overall in vitro fertilization market growth of the region.

Analysts at Fortune Business Insights said high expenses and risks related to the in vitro fertilization process (IVF) and Intracytoplasmic sperm injection (ICSI) may cause hindrance to the overall in vitro fertilization market revenue. Nevertheless, factors such as increasing obesity cases among people, infertility among men, the practice of sedentary lifestyle, and others are likely to create lucrative IVF market growth opportunities in the coming years.

Europe holds a dominant in vitro fertilization market share with a revenue of USD 7.57 billion generated in the year 2018. This is attributable to the rise in the prevalence of infertility and the increasing popularity of IVF treatment in the region. On the other side, the market in North America will witness steady growth on account of the high cost associated with ICSI and IVF treatment. As per the FertilityIQ data, 2017, in the U.S., the average expenditure of a patient undergoing a single IVF cycle is USD 22,000. Thus, patients in the U.S are travelling to other countries for IVF treatment citing lower costs.

Companies are Investing in Construction of New Fertility Centers for Revenue Generation

Boston IVF, Pelargos IVF, and Monash IVF are currently dominating the market. In vitro fertilization market manufacturers are developing new centers with efficient and high-quality treatment in remote locations for speeding their own revenue generation and making their mark in the market competition. This will ultimately accelerate the overall IVF market size.

Significant Industry Developments in In Vitro Fertilization Market:

May 2019 A new embryo screening test was developed by scientists at Monash IVF for reducing the risk of miscarriage at the time of IVF treatment.

July 2019 The opening of a new full-service IVF center at the Westshore office at Tampa, Florida, was announced by Shady Grove Fertility. The main objective behind the opening of this center is to offer affordable and high-quality fertility treatment options to the regional people.

List of key Companies Operating in the In Vitro Fertilization (IVF) Market include:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/in-vitro-fertilization-ivf-market-102189

Detailed Table of Content:

TOC Continued.!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/in-vitro-fertilization-ivf-market-102189

Have a Look at Related Reports:

In-vitro Diagnostics (IVD) Market Size, Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019 2026

Assisted Reproductive Technology (ART) Market Size, Share & Industry Analysis, By Technique (In-Vitro Fertilization (IVF), Artificial Insemination (AI-IUI), Frozen Embryo Transfer (FET), and Others), By Procedure (Fresh Donor, Fresh Non-donor, Frozen Donor, and Frozen Non-donor), By End User (Fertility Clinics, and Hospitals) and Regional Forecast, 2019-2026

Biomarkers Market Size, Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026

Neuroendoscopy Devices Market Size, Share & Industry Analysis, By Product Type (Rigid Neuroendoscopes, Flexible Neuroendoscopes), By Application Type (Transnasal Neuroendoscopy, Intraventricular Neuroendoscopy, Transcranial Neuroendoscopy), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2019-2026

Next-Generation Sequencing (NGS) Market Size, Share and Industry Analysis By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Regional Forecast, 2019 2026

Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 2026

Genomics Market Size, Share and Industry Analysis By Type (Products, Services), Technology (Polymerase Chain Reaction, Next-generation Sequencing, Microarray, Sanger Sequencing), Application (Diagnostics, Research), End-User (Research Institutes, Healthcare Facilities & Diagnostic Centers, Pharmaceutical & Biotechnological Companies, Contract Research Organization (CROs)) & Regional Forecast, 2019 - 2026

Contract Research Organization (CRO) Services Market Size, Share and Industry Analysis By Service Type (Discovery, Pre-Clinical, Clinical, Laboratory Services), By Application (Oncology, Cardiology, Infectious Disease, Metabolic Disorders, Others), By End User (Pharmaceutical & Biotechnological Companies, Medical Device Companies, Academic & Research Institutes, Others), and Regional Forecast 2019-2026

Immunology Market Size, Share and Industry Analysis By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressant, Polyclonal antibody (pAb), Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), By Distribution Channel, and Regional Forecast 2019-2026

Immunodiagnostics Market Size, Share and Industry Analysis By Product Instruments, Reagents & Consumables), By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases), By End user (Clinical Laboratories, Hospitals, Physicians Offices), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Regional Forecast, 2019 2026

Orthobiologics Market Size, Share and Industry Analysis by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), By End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics), and Regional Forecast 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/in-vitro-fertilization-ivf-market-9606

Excerpt from:
In Vitro Fertilization Market will Reach USD 36.39 Billion by 2026: Increasing Cases of Infertility Among Men to Positively Influence Growth, says...

Global Veterinary X-ray Market is Expected to Reach USD 1,167.47 Million by 2025 : Fior Markets – GlobeNewswire

Newark, NJ, Feb. 20, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal veterinary x-ray market is expected to grow from USD 651.07 Million in 2017 to USD 1,167.47 Million by 2025 at a CAGR of 7.81% during the forecast period from 2018-2025.

Radiology systems are the most preferred diagnostic tools a veterinarian uses to diagnose diseases in animals. It contains of diagnostic medical descriptions including ultrasound, magnetic resonance tomography, magnetic resonance imaging and atomic imaging. This is a non-invasive way to diagnose the disease. It is a painless procedure, however, animals are often anesthetized to reduce anxiety and stress during the procedure. The rise in the number of pets and the increase in awareness about the well-being of pets is driving the growth of this sector. According to the American Pet Products Association, in 2016, American families had approximately 35% of cats and 44% of dogs, making them around 85.8 million cats and 78 million dogs owned by the United States

The global market for veterinary X-rays is expected to grow rapidly during the forecast period, due to the increasing incidence of animal bone diseases, the increasing number of pets around the world, and the increase in the number of veterinary practitioners worldwide, as it is the main factor driving the market. The high cost of veterinary X-ray tools and the shortage of skilled veterinary technicians may limit market growth. However, high levels of pet insurance may boost future market opportunities.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/376062/request-sample

Key players operating in the global veterinary X-ray market are IDEXX Laboratories, Fujifilm, Onex Corporation, Agfa-Gevaert Group, Sound Technologies, Sedecal, Examion, Canon, DRE Veterinary, Heska Corporation, Fovea, Clearvet, Control-X Medical, Allpro Imaging, Vetel Diagnostics, Pixxgen and Konica Minolta among others. To enhance their market position in the global veterinary X-ray market, the key players are now focusing on adopting the strategies such as recent developments, product innovation, joint venture, mergers & acquisitions, collaborations, and partnership. Major firms are increasingly investing on research and development activities and development of newer products.

Computed radiography systems is dominating the segment and was valued around USD 286.44 Million in 2017

The technology segment is classified into computed radiography systems segment, direct radiography systems and film-based radiography systems. Computed radiography systems is dominating the segment and was valued around USD 286.44 Million in 2017. Increasing demand for affordable digital X-ray equipment and benefits offered by CR systems over other technologies are contributing for the growth of the segment.

The digital X-rays segment held the largest share of around 56.31% in 2017

Type section includes digital X-rays and analog X-rays. The digital X-rays segment held the largest share of around 56.31% in 2017. X-ray systems offer various benefits over analog systems, which include less costly, improved efficiency, and patient-centric imaging are some of the factors driving the growth of the segment.

The Stationary X-Ray Systems segment is dominated and expected to witness the highest market share of 56 % in the forecast period

The segment is classified into stationary x-ray systems and portable x-ray systems. The stationary x-ray systems is dominated and expected to witness the highest market share of 56% in the forecast period. While new technology advancement and rising use of portable x-ray systems are boosting this segment.

The small companion animals segment is dominated and is expected to held largest share of 61.17% in 2017

Animal type segment includes small companion animals and large animals. The small companion animals segment is dominated and is expected to held largest share of 61.17% in 2017. Increased adoption of pets, growing companionship and demand of highly accurate diagnostic solutions are boosting the growth of the segment.

The orthopedic & trauma segment is dominating and was valued around USD 214.83 million in 2017

Application segment is bifurcated into orthopedics & trauma, dental applications, oncology and other applications. Orthopedic & trauma segment is dominating and was valued around USD 214.83 million in 2017 due to increase in injuries among animals and availability of animal care facilities are contributing to the growth of the segment.

The veterinary hospitals & academic institutes segment is anticipated to grow with the highest CAGR of 9.14% in the forecast period

End user section includes veterinary hospitals & academic institutes and veterinary clinics. The veterinary hospitals & academic institutes segment is anticipated to grow with the highest CAGR of 9.14% in the forecast period. The growth can be accredited to developments in technologies for cost-effective, fast and precise diagnostic tools for animal healthcare.

Browse full report with TOC athttps://www.fiormarkets.com/report/global-veterinary-x-ray-market-by-technology-type-direct-376062.html

Regional Segment Analysis of the Veterinary X-ray market

The regions analysed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. North America region captured the largest share of global veterinary X-ray market and was valued in USD 318.99 Million in 2017 whereas Asia pacific is expected to attain the lucrative growth in the forecast period. North America region is expected to dominate the market due to pet adoption coupled with increasing healthcare expenditure and increase in R&D with growing demand for veterinary equipment. Asia pacific is expected to register the highest growth in the forecast period owing to growing demand for veterinary products and availability of low-cost animal health products are anticipated to drive the growth. Figured radiography and film-based radiography are inexpensive in this region as compared to industrialised regions.

About the report:

The global veterinary x-ray market is analysed on the basis of value (USD Million). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, supply, demand analysis, competitor position grid analysis, distribution and marketing channels analysis.

For Instant Purchase:

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash DHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://www.mrinsights.biz/

Related Reports

Global Breast Cancer Liquid Biopsy Market - https://www.fiormarkets.com/report/global-breast-cancer-liquid-biopsy-market-by-circulating-376049.htmlGlobal Cell Therapy Technologies Market - https://www.fiormarkets.com/report/global-cell-therapy-technologies-market-by-product-consumables-376050.htmlGlobal Dental 3D Printing Market - https://www.fiormarkets.com/report/global-dental-3d-printing-market-by-product-and-376051.htmlGlobal Gene Therapy Market - https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.html

Excerpt from:
Global Veterinary X-ray Market is Expected to Reach USD 1,167.47 Million by 2025 : Fior Markets - GlobeNewswire

Argentinian cultured meat supplier on its ‘all-in-one’ cell line: ‘We offer cells that can grow fast and reduce costs’ – FoodNavigator-Latam

Rather than developing a consumer-facing prototype, Cell Farm Food will supply the raw material to cultured meat companies and sell the stem cell lines through a royalty model.

The company has already taken part in several incubator and accelerator programs with Pro Veg (Berlin), Brinc (Hong Kong) and Grid Exponential (Buenos Aires) and will open a seed round to raise further funds in the coming months.

Cell Farm Food Tech, which counts a team of four women and has a presence in Buenos Aires, London, and Hong Kong, takes biopsies from Hereford and

Angus beef that form the main gene pool of Argentinian cattle and isolates the mesenchymal stem cells.

With these specific cells we can have an all-in-one cell line since they can differentiate into the main tissues present in the meat: muscle, adipocyte, bone, and cartilage, said Sofia Giampaoli, CEO and founder of the company. Mesenchymal stem cellsseem promising for scaling up cultured meat because they are, in simple terms, easy to grow. However, we are also working with induced pluripotent stem cells (iPS).

We are tackling a major opportunity the cultured meat industry has by offering immortalized lines that can grow faster and reduce manufacturing costs by using less cultured media.

Cell Farm Food Tech is also working on a method it says will allow the cells to grow between two and three times faster than the standard procedure but is not ready to disclose details yet.

It anticipates being able to offer stem cell lines to cultured meat companies within a matter of months, rather than years, so they can begin developing their own consumer-facing products,

Argentinas reputation as a premium beef producer and, vven if increasing numbers are fattened in feedlots before being slaughtered - anestimated 40% in 2012- the image of gauchos herding grass-fed cattle on the pampa is a selling point, particularly for consumers in countries like China.

Our idea is to leverage the countrys brand traditional meat production and its high-quality standards and to [expand] that to cultured meat, said Giampaoli, who is a chemical engineer by training and previously worked at PepsiCo.

Initial demand will come from international markets such as China, Europe, and the US, rather than within Latin America.

Latin Americans are not early adopters in terms of food. We are very traditional and the reality is we have high-quality meat in Argentina.

I am working so that Latin Americas politicians can see, as Chinas already did, the huge potential this technology has, she added. Latin America has to see cell ag technology as an opportunity and not a threat to the traditional industries.

Giampaoli intends to keep Cell Farm Food Techs R&D and production in Argentina - as long as it remains advantageous for the company. Although the country offers many benefits such as low operating costs, Argentinas notoriously volatile economy and complex red tape could force the company to relocate, she said.

Due to the extremely high costs of producing cultured meat at the minute, the products that will be available in the next three to four years are in fact cultured cells on a plant-based scaffold, Giampaoli said.

Giuseppe Scionti is CEO and co-founder of plant-based startup NovaMeat, which provides this scaffolding technology required by cultured meat start-ups. It is working on developing a plant-based scaffold that is functional in terms of its texture, taste, appearance and nutritional properties.

The plant-based scaffold provides a preliminary skeleton structure for the cells to live in, explained Scionti, who sits on Cell Farm Food Techs board of advisors.

Normally, you don't just grow the cells on a petri dish, instead you seed them or grow them within a scaffold, also called biomaterial or extracellular matrix, he told us.

Cell-based meat needs more than just the cells from the biopsies: in the last 30 years of tissue engineering, the most common strategy is to combine the cells with the scaffold and the signaling molecules, or growth factors, such as the cell-growth media and serum.

See original here:
Argentinian cultured meat supplier on its 'all-in-one' cell line: 'We offer cells that can grow fast and reduce costs' - FoodNavigator-Latam

Locking in and preserving your healthy stem cells has never been easier and more accessible as Acorn Biolabs partners with Coverdale Clinics. – Yahoo…

Appointments for stem cell & DNA collection now available.

TORONTO , Feb. 20, 2020 /CNW/ - With the rapid emergence of regenerative medicine therapies and genetic analysis testing reaching mainstream medicine, consumers are demanding increased opportunities to prepare for their future healthcare needs, including banking a viable source of cells to preserve their current health.

Acorn Biolabs (CNW Group/Acorn Biolabs)

To meet this growing demand, Acorn Biolabs, the leading non-invasive stem cell collection, cryopreservation and analysis company, today announced its partnership with Coverdale Clinics Inc., a premium network of specialty care clinics in Canada . Together, Acorn and Coverdale will help make stem cell collection more accessible and affordable in the West Greater Toronto Area .

Through their partnership, Coverdale Clinics' Oakville location be offering Acorn's non-invasive stem cell collection services. The simple process involves plucking a few hair follicles from a client's head, which are then analyzed and cryopreserved for future use.

Acorn's innovative solution for live cell collection enables the collection of stem cells without the need for surgery or other painful and invasive procedures, making stem cell collection for life-long storage significantly more affordable and accessible for everyone.

"Our partnership with Acorn Biolabs opens up a great opportunity for us to expand Coverdale Clinics service offering into the emerging regenerative medicine and geneticsmarket. We're pleased to be able to leverage our specialty clinic in Oakville to offer a service that improves access to exciting and novel health care technologies," said Chris Dalseg , BioScript Solutions' Vice President of Strategic Growth and Marketing. "We have always been at the forefront of providing innovative health care services to Canadians, and adding stem cell collection services from Acorn exemplifies our ongoing commitment."

Once stem cells are collected, Acorn uses its proprietary capabilities to keep cells alive during transportation before going into long term cryogenic storage. The process turns collected hair follicles into a highly valuable and accessible resource for further regenerative medicine and genetics. Not only are these stem cells securely stored for future use, but the company's scientists will also be able to extract critical genetic information through DNA tests, for clients that want it, that will unlock valuable data about a person's health over their lifetime.

"We are excited to bring Acorn's preventative, personalized healthcare services to more people through this partnership with Coverdale Clinics. The cells collected are a life-long resource for these clients, not only in regenerative medicine, but also for advanced analytics, helping to identify diseases even before the first symptom," said Dr. Drew Taylor , Co-founder and CEO at Acorn Biolabs Inc. "The partnership is an important extension for Acorn to serve health-minded individuals in more geographies, freezing the clock on their stem cells so they can use them later in life, when they will need them most."

Clients can book their non-invasive stem cell collection appointment in Oakville, Ontario through Acorn's website today at http://www.acorn.me

About Acorn Biolabs, Inc.

Story continues

Acorn helps you live a longer, healthier tomorrow by freezing the clock on your cells today. Founded in 2017 by Steven ten Holder, Patrick Pumputis and Dr. Drew Taylor and borne out of years of research, Acorn is a healthcare technology company based at Johnson & Johnson INNOVATION JLABS in Toronto . Acorn is focused on giving everyone the best chance to experience more healthy years with its easy, affordable and non-invasive stem cell collection, analysis and cryopreservation service. For more information, visit acorn.me.

About Coverdale Clinics

Coverdale Clinics is a premium network of specialty care clinics, providing patients with a safe, comfortable environment to receive specialty medications by infusion or injection. With more than 100 clinics nationwide, our nurses take a personalized approach to patient care that includes education and counselling to better support medication adherence.

About BioScript Solutions

BioScript Solutions is committed to helping patients with chronic illnesses achieve the best possible health outcomes. With our total care approach, we simplify access to complex, specialty drug therapies and deliver full-service specialty care solutions at every stage of the patient's treatment journey. Through our specialty pharmaceutical distribution, pharmacies, patient support programs and clinical services, BioScript has the capability to manage the needs of manufacturers, payors, prescribers and health care practitioners across Canada today, and tomorrow. To learn more, please visit bioscript.ca.

SOURCE Acorn Biolabs

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2020/20/c2552.html

Read the original post:
Locking in and preserving your healthy stem cells has never been easier and more accessible as Acorn Biolabs partners with Coverdale Clinics. - Yahoo...